Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People

HER2 Testing in Breast Cancer - 2023 Guideline Update

Therapeutic Advances in Medical Oncology

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer

Therapeutic Advances in Medical Oncology

Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: A multicenter real-world study

Journal of Managed Care and Specialty Pharmacy

Economic value of ribociclib in early breast cancer in the United States

Tumori

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Breast Cancer Research Foundation

A revolution in breast cancer prevention is underway—With AI mammogram-based risk assessment starting at 35

U.S. Food and Drug Administration

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

HR+ HER2- Breast Cancer Resource Center

Interview with Dr. Ashley Martinez: Breast Cancer During Pregnancy

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study

Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People

HER2 Testing in Breast Cancer - 2023 Guideline Update

Therapeutic Advances in Medical Oncology

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer

Therapeutic Advances in Medical Oncology

Dalpiciclib combined with endocrine therapy for patients with HR+/HER2- metastatic breast cancer: A multicenter real-world study

Journal of Managed Care and Specialty Pharmacy

Economic value of ribociclib in early breast cancer in the United States

Tumori

Switching CDK4/6 inhibitors to overcome toxicity in HR-positive/HER2-negative advanced breast cancer

Frontiers in Oncology

Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer

Clinical Breast Cancer

Evaluating the efficacy of neoadjuvant endocrine therapy in HER2-low versus HER2-negative breast cancer

Breast Cancer Research Foundation

A revolution in breast cancer prevention is underway—With AI mammogram-based risk assessment starting at 35

U.S. Food and Drug Administration

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

npj Breast Cancer

Imlunestrant with or without abemaciclib in advanced breast cancer: Safety analyses from the EMBER-3 trial

Journal of Clinical Medicine

Is genetic testing of HER2-negative metastatic breast cancer patients implemented into clinical practice? A retrospective analysis

Managing Adverse Events for Women Receiving Adjuvant Breast Cancer Treatment

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer